News for Tonix Pharmaceuticals Holding Corp. (0A4T.L)

TNX-801 is a single-dose, live virus vaccine in development to protect against mpox and smallpox TNX-801 protects immunocompromised animals from a lethal cha

Key Takeaways: Tonix Pharmaceuticals (TNXP) saw a significant stock decline, potentially overshadowing its strategic partnerships. Analysts remain optimi

\n The FDA has set a PDUFA date of August 15, 2025, for TNXP's TNX-102 SL fibromyalgia treatment, which has received Fast Track designation. A $34 million

CHATHAM, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. ( TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical com

**media[596623]**

Tonix Pharmaceuticals (TNXP) and Makana Therapeutics have announced a collaborative agreement to advance xenotransplantation therapies. The partnership

TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia TNX-102 SL demonstra

**media[587691]**

**media[583681]**

On Friday, March 28, 2025, U.S. stock markets experienced a significant downturn as investors grappled with rising inflation concerns and the looming threat

**media[578218]**

Market Analysis by covering: Tonix Pharmaceuticals Holding Corp, Lexeo Therapeutics Inc. Read 's Market Analysis on Investing.com

As of March 25, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading d...

On track for August 15, 2025 FDA PDUFA goal date TNX-102 SL is a non-opioid analgesic; if approved, TNX-102 SL would become the first new drug for treating fib

Clade I, the culprit in the current 2025 version of global epidemic mpox, is highly transmissible and is spreading within families and among children, whereas t

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday. Shares of Absci Corporation ABSI fell sharply in today's pr...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treat

On Tuesday, March 18, 2025, U.S. stock markets experienced a significant downturn, primarily driven by a sell-off in the technology sector. The decline came

NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced t...